The FDA drug database lists a supplement dated 8 October 2026 to an abbreviated new drug application for oxcarbazepine held by a generic manufacturer. The record gives only the application number and the company, with no detail of what changed.
Supplements to generic applications are commonly manufacturing or labelling updates and do not amount to a new indication or a safety warning. This entry gives no reason to alter prescribing. Prescribers should work from the product information for the brand they supply, and in India from CDSCO-approved labelling.
- No new indication or safety communication is described in this record
- Check the labelling for the product your pharmacy supplies
- Keep established monitoring for oxcarbazepine, such as sodium checks where indicated
- Indian labelling is set by CDSCO and may differ from US documents
Why it matters
A database entry for a generic is easily mistaken for a safety change.
Don't overread it
A licence supplement is not a new indication, and the record carries no safety finding.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for neurology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free